Progress of DPP-4 inhibitors and upper respiratory tract infection

To explore the relationship between DPP-4 inhibitors and upper respiratory tract infection.In order to provide reference for clinical treatment, the clinical research of DPP-4 inhibitors in recent years on the upper respiratory tract infections were retrieved and analyzed.Adverse drug reaction analysis of DPP-4 inhibitors prompted an increase in the risk of upper respiratory tract infections, but the subsequent clinical studies did not confirm this view.There were two studies demonstrated saxagliptin had seen a slight increase in the incidence of upper respiratory tract infection slightly when combined with metformin, but other DPP-4 inhibitors have not been proven to increase the infection of the upper respiratory tract.Saxagliptinwhen combined with metforminmay may increase the upper respiratory tract infection, but further confirmation is required.Other DPP-4 inhibitors are not found to increase respiratory tract infections. Key words: Type 2 diabetes; Antidiabetic drugs; DPP-4 inhibitors; Upper respiratory tract infection